JW Life Science Q1 2026 Results: Consolidated Operating Profit Up, Dividend Maintained

Q1 2026 consolidated revenue KRW 63.5bn (down 7.4% YoY), operating profit KRW 9.3bn (up slightly), net profit KRW 6.7bn (up 9.5% YoY)
Separate revenue KRW 59.3bn (down 4.5% YoY), operating profit KRW 8.9bn (up 31% YoY), net profit KRW 6.2bn (down 12.4% YoY)
Dividend of KRW 500 per share (total KRW 8.5bn) maintained
Total borrowings decreased 17.6% to KRW 40.3bn, improving financial structure
Operating cash flow KRW 15.3bn, up 30.8% YoY
Domestic market share: basic IV fluids 42.9%, TPN 48.5%
R&D expenditure KRW 1.5bn (2.53% of revenue)
Contingent liabilities: guarantees to affiliates KRW 13.9bn, collateral assets KRW 137.1bn